SCOPUS 정보 검색 플랫폼

Volumn 32, Issue 17, 2014, Pages 1855-

Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 guidelines

(2) Rohit, Bhargava a Dabbs, David J a

a UNIVERSITY OF PITTSBURGH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CHROMOSOME 17; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84905828649 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2013.53.9213 Document Type: Letter

Times cited : (18)

References (5)

1
- 33847147313
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
- DOI 10.1200/JCO.2006.09.2775
- Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.1 , pp. 118-145
- Wolff, A.C.¹ Hammond, M.E.H.² Schwartz, J.N.³ Hagerty, K.L.⁴ Allred, D.C.⁵ Cote, R.J.⁶ Dowsett, M.⁷ Fitzgibbons, P.L.⁸ Hanna, W.M.⁹ Langer, A.¹⁰ McShane, L.M.¹¹ Paik, S.¹² Pegram, M.D.¹³ Perez, E.A.¹⁴ Press, M.F.¹⁵ Rhodes, A.¹⁶ Sturgeon, C.¹⁷ Taube, S.E.¹⁸ Tubbs, R.¹⁹ Vance, G.H.²⁰ more..

2
- 84890254448
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
- Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
- (2013) J Clin Oncol , vol.31 , pp. 3997-4013
- Wolff, A.C.¹ Hammond, M.E.² Hicks, D.G.³

3
- 67649989634
- Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA trial
- Dowsett M, Procter M, McCaskill-Stevens W, et al: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA trial. J Clin Oncol 27:2962-2969, 2009
- (2009) J Clin Oncol , vol.27 , pp. 2962-2969
- Dowsett, M.¹ Procter, M.² McCaskill-Stevens, W.³

4
- 80755166082
- Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti- HER2 targeted therapy
- Tse CH, Hwang HC, Goldstein LC, et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti- HER2 targeted therapy. J Clin Oncol 29:4168-4174, 2011
- (2011) J Clin Oncol , vol.29 , pp. 4168-4174
- Tse, C.H.¹ Hwang, H.C.² Goldstein, L.C.³

5
- 78049431141
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
- Perez EA, Reinholz MM, Hillman DW, et al: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307-4315, 2010
- (2010) J Clin Oncol , vol.28 , pp. 4307-4315
- Perez, E.A.¹ Reinholz, M.M.² Hillman, D.W.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.